Glenmark Carvedilol Lawsuit: A Carcinogen Limit, 732,960 Bottles, and a Refund Fight
Glenmark's generic <strong>carvedilol</strong> — a beta-blocker millions take for blood pressure and heart failure — was recalled in 2025 after nitrosamine contamination, and on <strong>4 August 2026</strong> a class action followed. Precision matters here: the lawsuit is about <strong>money paid for adulterated pills</strong>, not about anyone's cancer. No court has linked these tablets to any illness, and the case itself makes no injury claim. If you bought Glenmark carvedilol, this page shows you how to check your bottle and what the case seeks.
Editorially Reviewed — Content reviewed for accuracy using published legal research, government data, and verified court records. See our methodology
Reviewed by Leonard Goldberg, Editor · Last updated
What the Lawsuit Alleges
Sharon Carroll, a Washington State patient who bought Glenmark carvedilol between March 2024 and July 2025, sued Glenmark Pharmaceuticals alleging the tablets contained N-Nitroso-Carvedilol I — a nitrosamine impurity the FDA and IARC treat as a probable human carcinogen — above the FDA's acceptable-intake limit of 4.0 ppm. The complaint pleads nine counts, from Magnuson-Moss warranty claims through fraud, negligent misrepresentation, state consumer-protection violations and unjust enrichment, and alleges Glenmark had actual or constructive knowledge of nitrosamine risk in its manufacturing well before recalling. It seeks refunds and replacement costs, restitution, punitive damages and an injunction for a nationwide class of purchasers plus a Washington subclass. Glenmark has not yet answered. The complaint claims economic harm only — it does not allege that any plaintiff developed cancer or was physically injured.
Case Details
The case is Carroll v. Glenmark Pharmaceuticals, Case No. 2:26-cv-00327, in the U.S. District Court for the Eastern District of Washington, filed 4 August 2026 by Tousley Brain Stephens PLLC. The recall behind it: Glenmark initiated a voluntary recall of carvedilol tablets in early August 2025, which the FDA classified as Class II in mid-August 2025 — covering 732,960 bottles across the 3.125 mg, 12.5 mg and 25 mg strengths, manufactured by Glenmark Pharmaceuticals Ltd. (India) and distributed by its New Jersey-based U.S. arm.
Status as of 24 August 2026
Were Your Pills Affected — the NDC Check
Check the NDC number on your bottle or pharmacy label against the recalled Glenmark carvedilol NDCs (reported across the recall coverage: 68462-162-01, 68462-162-05, 68462-164-01, 68462-164-05, 68462-165-05; the complaint itself references packages under 68462-0163 and 68462-0164). Your pharmacy can confirm in seconds whether your fills came from a recalled lot — pharmacies logged these recalls when they happened. If your bottle matches: photograph the label, keep the bottle and any receipts or insurance statements, and do not throw it away — that label is the entire proof of purchase a future claims process would ask for. On the medical side: do not stop taking a beta-blocker on your own; abrupt carvedilol discontinuation carries real cardiac risk, and every recall notice says to consult the prescriber first.
What the Case Could Pay — and What It Won't
How This Case Developed
- 1
March 2024 – July 2025 — the purchase window pleaded
The named plaintiff buys Glenmark carvedilol repeatedly; the class period for other purchasers will be defined in certification briefing.
- 2
Early August 2025 — the recall
Glenmark voluntarily recalls carvedilol tablets; the FDA classifies it Class II in mid-August 2025. 732,960 bottles across three strengths are covered.
- 3
2025–2026 — investigations begin
Consumer firms, including The Block Firm, open investigations into purchasers' refund claims.
- 4
4 August 2026 — the class action
Carroll v. Glenmark Pharmaceuticals is filed in the Eastern District of Washington, No. 2:26-cv-00327, pleading nine counts of economic-harm claims.
- 5
Next — answer and certification fight
Glenmark's response, then motions practice. No settlement exists; refunds, if any, are years away absent early resolution.
Three Things to Ignore
Drug-recall lawsuits breed a specific kind of predatory noise.
'Carvedilol cancer payout' ads
No court has linked these tablets to any cancer, and this lawsuit claims refunds, not injuries. Ads promising cancer settlements for carvedilol users describe litigation that does not exist.
Stop-your-meds panic content
Stopping a beta-blocker abruptly is dangerous. Every legitimate recall notice routes you to your prescriber — content urging you to bin your pills without a doctor is a health hazard dressed as consumer advice.
Paid 'recall refund' claim services
There is no claims process to file into. Keeping your bottle, label and receipts costs nothing and is the only preparation that matters today.
Common Questions
Is there a settlement or refund program?
No. The class action was filed 4 August 2026 and is at the earliest stage. Keep proof of purchase; there is nothing to file yet.
Did these pills give anyone cancer?
No such claim exists in this case or anywhere in the public record we reviewed. The lawsuit is about purchases of adulterated product, and nitrosamine limits are set precisely to keep long-term exposure risk low.
How do I check if my bottle was recalled?
Match the NDC number on your label against the recalled NDCs listed above, or ask your pharmacy to check your fill history — they can see it immediately.
Should I stop taking my carvedilol?
Not on your own. Abruptly stopping a beta-blocker carries cardiac risk. Talk to your prescriber or pharmacist about whether your supply was affected and what to switch to.
What is a nitrosamine, in one paragraph?
A class of chemical impurities that can form during drug manufacturing. Several are probable human carcinogens at sustained high exposure, which is why the FDA sets strict acceptable-intake limits — 4.0 ppm here — and forces recalls when testing exceeds them. The same impurity family drove the big valsartan, ranitidine (Zantac) and metformin recalls.
What is a Class II recall?
The FDA's middle tier: use of the product may cause temporary or medically reversible adverse effects, with serious outcomes considered unlikely. It sits awkwardly beside the carcinogen language — both statements are the agencies' own.
Who is investigating besides the named plaintiff's firm?
The Block Firm, LLC has an active investigation taking purchaser inquiries. The named case is litigated by Tousley Brain Stephens PLLC of Seattle.
How do I verify this page?
Through the E.D. Wash. docket for No. 2:26-cv-00327, the FDA enforcement-report entries for the August 2025 Glenmark carvedilol recall, and the recall coverage cited here, as read on 24 August 2026.
Separate from this case: were you injured in the last 2 years?
Class-action payouts are fixed amounts through an administrator. A personal injury claim is a different case — and often worth far more. Free estimate, no obligation.